Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder
NCT07809724Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Peking University People's Hospital. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
aldesleukin
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT07809724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809724.